

Is It Safe To Switch Biosimilars?

Written by The Life Science Feed Editorial Team · Published 28 May 2026 · Edited by James Carter

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Jorgensen KK et al. NOR-SWITCH: switching from reference infliximab to biosimilar CT-P13. *Lancet*. 2017;389:2304-2316
2. Gerdes S et al. Biosimilar use in dermatology: switching from adalimumab originator to biosimilar. *J Eur Acad Dermatol Venereol*. 2020;34:2272-2280
3. Warren RB et al. Secukinumab biosimilar SB17 vs reference secukinumab in psoriasis. *Br J Dermatol*. 2024
4. Blauvelt A et al. Switching from originator to biosimilar: systematic review in dermatology. *J Dermatol Sci*. 2021;103:143-150
5. EMA. Biosimilar medicines: questions and answers. European Medicines Agency. 2022

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com